Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.31
+4.0%
$1.74
$1.21
$7.97
$45.38M1.09144,281 shs760 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$6.85
$8.87
$3.78
$13.62
$378.26M1.67181,023 shs10,675 shs
RenovaCare, Inc. stock logo
RCAR
RenovaCare
$0.00
$0.00
$0.30
$10K12,701 shs650 shs
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$9.54
$8.53
$5.48
$14.23
$354.92M1.31822,700 shs1.16 million shs
The Westaim Co. stock logo
WEDXF
Westaim
$2.71
+0.4%
$2.67
$2.13
$2.99
$348.23M0.4632,256 shs4,686 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-4.55%-8.70%+0.80%-43.50%-56.55%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-4.73%-12.40%-23.55%-30.67%+15.71%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.00%0.00%0.00%0.00%-99.85%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.00%0.00%0.00%0.00%0.00%
The Westaim Co. stock logo
WEDXF
Westaim
+0.37%+3.83%-0.88%+0.93%+23.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.7832 of 5 stars
3.54.00.04.20.01.70.6
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17370.74% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.87N/AN/A$0.78 per share1.68
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K540.37N/AN/A$0.81 per share8.46
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
$191.45M1.85N/AN/A$8.57 per share1.11
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M40.50$1.41 per share1.92$3.95 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/9/2024 (Estimated)
RenovaCare, Inc. stock logo
RCAR
RenovaCare
-$4.47MN/A0.00N/AN/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
-$54.35M-$1.77N/AN/AN/A-28.22%-22.16%-17.09%N/A
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.08N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest APYX, WEDXF, SPNE, RCAR, and PLSE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/27/2024Q4 2023
The Westaim Co. stock logo
WEDXF
Westaim
N/A$0.26+$0.26$0.26N/A$1.67 million
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/AN/AN/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
0.09
3.18
1.65
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
N/A
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
70.81%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%
RenovaCare, Inc. stock logo
RCAR
RenovaCare
0.86%
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
9.32%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable
RenovaCare, Inc. stock logo
RCAR
RenovaCare
187.35 million86.60 millionNot Optionable
SeaSpine Holdings Co. stock logo
SPNE
SeaSpine
52337.20 million33.74 millionOptionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.97 million123.54 millionNot Optionable

APYX, WEDXF, SPNE, RCAR, and PLSE Headlines

SourceHeadline
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM
Heres what Wall Street expects from Westaims earnings reportHere's what Wall Street expects from Westaim's earnings report
markets.businessinsider.com - April 6 at 12:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
RenovaCare logo

RenovaCare

OTCMKTS:RCAR
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
SeaSpine logo

SeaSpine

NASDAQ:SPNE
As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.